Immatics N.V.
IMTXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeImmatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company carries a $1.31B market cap, placing it firmly in the small-cap category. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
Market Cap
$1.31B
Beta
1.32
P/E (TTM)
—
P/E (Fwd)
-5.04
EPS (TTM)
$-1.99
EPS (Fwd)
$-1.90
ROE
-43.2%
ROA
-22.4%
Cash
$453.6M
Total Debt
$15.1M
Free CF
-$110.9M
52W Change
59.8%
Annual Financials
Cash vs Debt
With $453.6M in cash and $15.1M in debt, IMTX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$110.9M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -43.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $172.8M (2022) to $48.3M (2025), a 72% decline worth watching.
With cash comfortably exceeding debt, IMTX has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing IMTX.